Literature DB >> 23928187

Differential regulation of CYP3A4 promoter activity by a new class of natural product derivatives binding to pregnane X receptor.

Monimoy Banerjee1, Taosheng Chen.   

Abstract

The pregnane X receptor (PXR) regulates drug metabolism by regulating the expression of drug-metabolizing enzymes such as cytochrome P450 3A4 (CYP3A4), which is involved in the metabolism of >50% of clinically prescribed drugs. The activity of PXR can be controlled by the binding of small molecule agonists or antagonists. Because of its unique ligand binding pocket, PXR binds promiscuously to structurally diverse chemicals. To study the structure-activity relationship, novel modulators for PXR are needed. Here we report the virtual screening of ∼25,000 natural product derivatives from the ZINC database using the Molecular Operating Environment docking software tool against the PXR-rifampicin complex X-ray crystal structure. Our screening resulted in identification of compounds based on the lowest S score, which measures Gibbs free energy. Interestingly, we found that the compounds that bind directly to PXR, as revealed in an intrinsic tryptophan fluorescence assay, modulate CYP3A4 promoter activity differentially in HepG2 cells. Mutational analysis and docking studies showed that these compounds bind broadly in the ligand binding pocket but interact with different amino acid residues. We further investigated the mechanism of binding by analyzing the functional groups that are important for distinguishing agonists from antagonists. The approach we used to identify novel modulators that bind to PXR can be useful for finding novel modulators of PXR.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Drug metabolism; Molecular docking; Natural product derivative; PXR

Mesh:

Substances:

Year:  2013        PMID: 23928187      PMCID: PMC3777815          DOI: 10.1016/j.bcp.2013.07.023

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  48 in total

Review 1.  Orphan nuclear receptor-mediated xenobiotic regulation in drug metabolism.

Authors:  Wen Xie; Hirdesh Uppal; Simrat P S Saini; Ying Mu; Joanna M Little; Anna Radominska-Pandya; Michael A Zemaitis
Journal:  Drug Discov Today       Date:  2004-05-15       Impact factor: 7.851

2.  Camptothecin attenuates cytochrome P450 3A4 induction by blocking the activation of human pregnane X receptor.

Authors:  Yakun Chen; Yong Tang; Gregory T Robbins; Daotai Nie
Journal:  J Pharmacol Exp Ther       Date:  2010-05-26       Impact factor: 4.030

3.  Repression of PXR-mediated induction of hepatic CYP3A gene expression by protein kinase C.

Authors:  Xunshan Ding; Jeff L Staudinger
Journal:  Biochem Pharmacol       Date:  2005-01-21       Impact factor: 5.858

4.  The dietary isothiocyanate sulforaphane is an antagonist of the human steroid and xenobiotic nuclear receptor.

Authors:  Changcheng Zhou; Emma-Jane Poulton; Felix Grün; Theo K Bammler; Bruce Blumberg; Kenneth E Thummel; David L Eaton
Journal:  Mol Pharmacol       Date:  2006-10-06       Impact factor: 4.436

5.  Regulation and binding of pregnane X receptor by nuclear receptor corepressor silencing mediator of retinoid and thyroid hormone receptors (SMRT).

Authors:  David R Johnson; Chia-Wei Li; Liuh-Yow Chen; Jagadish C Ghosh; J Don Chen
Journal:  Mol Pharmacol       Date:  2005-10-11       Impact factor: 4.436

6.  Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen.

Authors:  Pankaj B Desai; Srikanth C Nallani; Rucha S Sane; Linda B Moore; Bryan J Goodwin; Donna J Buckley; Arthur R Buckley
Journal:  Drug Metab Dispos       Date:  2002-05       Impact factor: 3.922

7.  Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites.

Authors:  Sean Ekins; Cheng Chang; Sridhar Mani; Matthew D Krasowski; Erica J Reschly; Manisha Iyer; Vladyslav Kholodovych; Ni Ai; William J Welsh; Michael Sinz; Peter W Swaan; Rachana Patel; Kenneth Bachmann
Journal:  Mol Pharmacol       Date:  2007-06-18       Impact factor: 4.436

8.  A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor.

Authors:  Christine Healan-Greenberg; Jeffrey F Waring; Dale J Kempf; Eric A G Blomme; Rommel G Tirona; Richard B Kim
Journal:  Drug Metab Dispos       Date:  2007-12-20       Impact factor: 3.922

9.  Sesamin: A Naturally Occurring Lignan Inhibits CYP3A4 by Antagonizing the Pregnane X Receptor Activation.

Authors:  Yun-Ping Lim; Chia-Yun Ma; Cheng-Ling Liu; Yu-Hsien Lin; Miao-Lin Hu; Jih-Jung Chen; Dong-Zong Hung; Wen-Tsong Hsieh; Jin-Ding Huang
Journal:  Evid Based Complement Alternat Med       Date:  2012-05-07       Impact factor: 2.629

10.  The phytoestrogen coumestrol is a naturally occurring antagonist of the human pregnane X receptor.

Authors:  Hongwei Wang; Hao Li; Linda B Moore; Michael D L Johnson; Jodi M Maglich; Bryan Goodwin; Olivia R R Ittoop; Bruce Wisely; Katrina Creech; Derek J Parks; Jon L Collins; Timothy M Willson; Ganjam V Kalpana; Madhukumar Venkatesh; Wen Xie; Sool Y Cho; John Roboz; Matthew Redinbo; John T Moore; Sridhar Mani
Journal:  Mol Endocrinol       Date:  2007-12-20
View more
  11 in total

Review 1.  Drug discovery technologies to identify and characterize modulators of the pregnane X receptor and the constitutive androstane receptor.

Authors:  Sergio C Chai; Wenwei Lin; Yongtao Li; Taosheng Chen
Journal:  Drug Discov Today       Date:  2019-02-04       Impact factor: 7.851

Review 2.  Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery.

Authors:  Ogheneochukome Lolodi; Yue-Ming Wang; William C Wright; Taosheng Chen
Journal:  Curr Drug Metab       Date:  2017       Impact factor: 3.731

Review 3.  Targeting xenobiotic receptors PXR and CAR in human diseases.

Authors:  Monimoy Banerjee; Delira Robbins; Taosheng Chen
Journal:  Drug Discov Today       Date:  2014-11-20       Impact factor: 7.851

Review 4.  Why We Need to Take a Closer Look at Genetic Contributions to CYP3A Activity.

Authors:  Qinglian Zhai; Maaike van der Lee; Teun van Gelder; Jesse J Swen
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988

5.  Development and Experimental Validation of Regularized Machine Learning Models Detecting New, Structurally Distinct Activators of PXR.

Authors:  Steffen Hirte; Oliver Burk; Ammar Tahir; Matthias Schwab; Björn Windshügel; Johannes Kirchmair
Journal:  Cells       Date:  2022-04-07       Impact factor: 7.666

6.  Thiazide-like diuretic drug metolazone activates human pregnane X receptor to induce cytochrome 3A4 and multidrug-resistance protein 1.

Authors:  Monimoy Banerjee; Taosheng Chen
Journal:  Biochem Pharmacol       Date:  2014-08-30       Impact factor: 5.858

7.  Garcinoic Acid Is a Natural and Selective Agonist of Pregnane X Receptor.

Authors:  Desirée Bartolini; Francesca De Franco; Pierangelo Torquato; Rita Marinelli; Bruno Cerra; Riccardo Ronchetti; Arne Schon; Francesca Fallarino; Antonella De Luca; Guido Bellezza; Ivana Ferri; Angelo Sidoni; William G Walton; Samuel J Pellock; Matthew R Redinbo; Sridhar Mani; Roberto Pellicciari; Antimo Gioiello; Francesco Galli
Journal:  J Med Chem       Date:  2020-03-20       Impact factor: 7.446

8.  Mutation of a single amino acid of pregnane X receptor switches an antagonist to agonist by altering AF-2 helix positioning.

Authors:  Andrew D Huber; William C Wright; Wenwei Lin; Kinjal Majumder; Jonathan A Low; Jing Wu; Cameron D Buchman; David J Pintel; Taosheng Chen
Journal:  Cell Mol Life Sci       Date:  2020-03-30       Impact factor: 9.261

9.  Tryptophan 299 is a conserved residue of human pregnane X receptor critical for the functional consequence of ligand binding.

Authors:  Monimoy Banerjee; Sergio C Chai; Jing Wu; Delira Robbins; Taosheng Chen
Journal:  Biochem Pharmacol       Date:  2016-02-18       Impact factor: 5.858

10.  Exploring the PXR ligand binding mechanism with advanced Molecular Dynamics methods.

Authors:  Stefano Motta; Lara Callea; Sara Giani Tagliabue; Laura Bonati
Journal:  Sci Rep       Date:  2018-11-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.